3303 Monte Villa Parkway
54 articles with BioLife Solutions
Revenue increases 102% to $5.2 million. Net income of $1.0 million achieved
M&A Activities to Focus on Cell and Gene Manufacturing Tools
BioLife Solutions to Report Second Quarter 2018 Financial Results and Provide Business Update on August 9, 2018
BioLife Solutions, Inc. announced that the Company's second quarter 2018 financial results will be released before market open on Thursday, August 9, 2018, and that the Company will host a conference call and live webcast at 10:00 a.m. ET (7:00 a.m. PT) that morning. Management will provide an overview of the Company's financial results and a general business update.
Investment Firm to Purchase Shares from Existing Holders
BioLife Solutions Reports Second Quarter 2018 Preliminary Revenue of $5.2 Million, up 103% Year-over-Year and 36% Sequentially
Full Year 2018 Revenue Guidance Increased
BioLife Solutions, Inc. today announced Michael Rice, CEO, and Roderick de Greef, CFO, will be attending and presenting at the 2018 BIO International Convention.
BioLife Solutions to Report First Quarter 2018 Financial Results and Provide Business Update on May 10, 2018
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media ("BioLife" or the "Company"), today announced that the Company's first quarter 2018 financial results will be released after market close on Thursday, May 10, 2018, and that the Company will host a conference call and live webcast at 1:30 p.m. PT that afternoon
BioLife Solutions, Inc. is a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media.
BioLife Solutions, Inc., announced that Casdin Capital LLC has entered into an agreement to purchase 1,000,000 BioLife Solutions common shares in a private transaction from the Company's second largest shareholder, who has been a primary source of investment capital for the Company since its inception.
BioLife Solutions Announces Preliminary First Quarter 2018 Revenue of $3.8 Million, up 61% Year-over-Year and 22% Sequentially
2018 Revenue Guidance Revised Upward
BioLife Solutions and SAVSU Technologies to be Awarded Second Patent for Next Generation Cold Chain Technologies Designed for Cell and Gene Therapies
BioLife Solutions Inc. and SAVSU Technologies announced that the USPTO has issued a notice of allowance for a second patent application titled "Biologic Stability, Delivery Logistics and Administration of Time and/or Temperature Sensitive Biologic Based Materials".
BioLife Solutions today announced that it has executed an OEM agreement to supply its CryoStor cell freeze media and HypoThermosol cell storage and shipping media under private label to MilliporeSigma, the life science business of Merck KGaA, Darmstadt, Germany.
BioLife today announced preliminary Q4 and full year 2017 revenue and provided additional operational updates and financial guidance for 2018.
BioLife Solutions today announced that it has executed an agreement to supply its CryoStor cell freeze media and HypoThermosol cell storage and shipping media to Iovance Biotherapeutics.